HIV vaccines.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

HIV vaccines.

Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:22 (abstract no. FPI-1). Unique Identifier : AIDSLINE ASHM5/94348939
Corey L; McElrath J; Kent S; Greenberg P; University of Washington, Seattle.

Abstract: To date the NIAID sponsored AIDS Vaccine Evaluation Group (AVEU) has enrolled over 1000 patients into Phase I/II clinical trials of candidate HIV vaccines. 8 different envelope products have been evaluated including two gp160 preparations, two subunit gp120 products, one yeast derived gp120, one vaccinia gp160, 1 canarypox gp160, and one envelope peptide based vaccine. All the vaccines have been immunogenic and adverse effects have been limited to transient local reactions. Direct comparison of immune responses is not possible in all cases due to varying stages of development, the varying doses of vaccine and the different adjuvants employed in the products. Overall, the two gp120 products have proven to elicit the highest neutralising antibody titers among health seronegative vaccines. Over 90% of recipients receiving a 0, 1, 6 month regimen have detectable neutralising responses; the mean neutralising titer average about 1:100, about 5-fold lower than that seen with persons with naturally acquired HIV infection. T cell lymphoproliferative responses are elicited by all of these vaccines However, none of the subunit vaccines alone have elicited detectable CD8+ cytolytic activity to HIV envelope (0 of 40 tested). However, 2 of 8 vaccinia naive individuals who have received a regimen consisting of priming with a vaccinia recombinant and boosting with a gp160 subunit protein have had detectable persistent CD8+ CTLs. A detailed description of the above Phase I and II trials will be given.

Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*PREVENTION & CONTROL AIDS Vaccines/*ADMINISTRATION & DOSAGE/IMMUNOLOGY Human HIV Antibodies/BIOSYNTHESIS HIV Envelope Protein gp120/ADMINISTRATION & DOSAGE/IMMUNOLOGY HIV Infections/IMMUNOLOGY/*PREVENTION & CONTROL Immunization Schedule Vaccines, Synthetic/ADMINISTRATION & DOSAGE/IMMUNOLOGY CLINICAL TRIAL CLINICAL TRIAL, PHASE I CLINICAL TRIAL, PHASE II ABSTRACT
941230
M94C4288

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .